In order to investigate if the 19-BM can improve on the current state-of-the-art clinical prognosticators, the SVM-based scores from 19-BM were further compared with the estimates of ERSPC risk calculator for detecting high risk PCa (ERSPC-3/4), as presented in Fig. 2C. Based on the available clinical data for the PSA levels, the DRE result and accounting also for the previous biopsies, ERSPC-3/4 estimates for 109 PCa patients were available for this comparison. The gene discussed is KLK3; the disease is posterior cortical atrophy.